- Adragos Pharma has announced a leadership transition, with Founder Dr. Andreas Raabe stepping down as CEO and Kostas Rengis appointed as his successor effective May 1.
- Dr. Raabe will remain a shareholder and advisor, while the company focuses on strengthening its CDMO platform and operational integration.
Adragos Pharma has announced a leadership transition as the company marks six years since its founding. Founder Dr. Andreas Raabe will step down from his role as Chief Executive Officer, with Kostas Rengis set to assume the position effective May 1.
The company stated that Dr. Raabe will remain a shareholder and continue to support Adragos in an advisory capacity. During his tenure, Adragos expanded into a multinational contract development and manufacturing organization (CDMO), operating across six sites in five countries.
Kostas Rengis brings experience in managing international multi-site pharmaceutical operations, including manufacturing, commercial, and research and development functions. The company indicated that under his leadership, the focus will be on strengthening its platform, integrating capabilities across its network, and ensuring consistent delivery to customers.
The transition includes a defined handover period aimed at maintaining continuity for customers, partners, and employees. The company stated that this approach is intended to support ongoing operational reliability during the leadership change.
